In this webcast our market access experts Suzan Serip and George Forsyth share insights on how biopharmaceutical companies can keep up during one of the largest healthcare and economic crises in recent times. Using data from the first wave of our COVID-19 impact payer research, they discuss the impact COVID-19 is currently having on the market access landscape as well as stakeholder evidence requirements, healthcare spending and policy.
In addition, they discuss SARS-CoV-2 vaccine pricing expectations, analyse recent procurement deals of major manufacturers as well as explore what factors pharmaceutical companies need to consider in the future.
What are the key takeaways?
- News in brief: A quick summary of all the latest COVID-19 developments
- The here and now: Discover the effect Coronavirus is currently having on pricing and market access activity
- Looking to the future: The likely impact on the market access landscape